Daniel Dolan

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
King Of Prussia, PA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ J. Christopher Naftzger, by power of attorney
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Daniel Dolan

Form 4 holding Chief Financial Officer

Nabriva Therapeutics plc

Security class
Stock Appreciation Right
Shares / value
83,200
Estimated value
Report date
11 Aug 2022
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Chief Financial Officer

Nabriva Therapeutics plc

Security class
Phantom Shares
Shares / value
41,600
Estimated value
Report date
11 Aug 2022
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Chief Financial Officer

Nabriva Therapeutics plc

Security class
Restricted Stock Units
Shares / value
0
Estimated value
Report date
11 Aug 2022
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Chief Financial Officer

Nabriva Therapeutics plc

Security class
Share Options
Shares / value
0
Estimated value
Report date
11 Aug 2022
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount

Insider Reports Filed by Daniel Dolan

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .